Wall Street brokerages expect that Crispr Therapeutics AG (NASDAQ:CRSP) will post $3.00 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Crispr Therapeutics’ earnings. The highest sales estimate is $4.00 million and the lowest is $2.00 million. Crispr Therapeutics posted sales of $1.09 million during the same quarter last year, which would indicate a positive year over year growth rate of 175.2%. The company is expected to announce its next earnings results on Tuesday, August 6th.
On average, analysts expect that Crispr Therapeutics will report full year sales of $7.83 million for the current financial year, with estimates ranging from $4.00 million to $15.00 million. For the next year, analysts anticipate that the business will report sales of $19.33 million, with estimates ranging from $8.00 million to $40.00 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, April 29th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.03). Crispr Therapeutics had a negative return on equity of 50.90% and a negative net margin of 8,839.02%. The firm had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $1.50 million. During the same quarter last year, the company posted ($0.62) EPS. The firm’s revenue was down 78.6% on a year-over-year basis.
In other Crispr Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the business’s stock in a transaction on Monday, April 29th. The shares were sold at an average price of $42.03, for a total transaction of $840,600.00. Following the completion of the sale, the chief executive officer now directly owns 186,542 shares in the company, valued at approximately $7,840,360.26. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, President Rodger Novak sold 14,780 shares of the business’s stock in a transaction on Monday, February 25th. The shares were sold at an average price of $40.00, for a total transaction of $591,200.00. Following the sale, the president now owns 1,033,227 shares of the company’s stock, valued at $41,329,080. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 128,693 shares of company stock valued at $5,222,495. Company insiders own 37.70% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Valeo Financial Advisors LLC boosted its stake in Crispr Therapeutics by 71.4% in the first quarter. Valeo Financial Advisors LLC now owns 725 shares of the company’s stock valued at $26,000 after acquiring an additional 302 shares in the last quarter. Flagship Harbor Advisors LLC lifted its holdings in shares of Crispr Therapeutics by 22.1% in the 1st quarter. Flagship Harbor Advisors LLC now owns 3,309 shares of the company’s stock worth $118,000 after acquiring an additional 600 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of Crispr Therapeutics by 6.0% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 11,034 shares of the company’s stock worth $395,000 after acquiring an additional 628 shares during the last quarter. Creative Planning lifted its holdings in shares of Crispr Therapeutics by 4.7% in the 1st quarter. Creative Planning now owns 15,486 shares of the company’s stock worth $553,000 after acquiring an additional 695 shares during the last quarter. Finally, Kore Private Wealth LLC acquired a new position in shares of Crispr Therapeutics in the 1st quarter worth approximately $27,000. Institutional investors and hedge funds own 43.71% of the company’s stock.
Shares of CRSP stock traded down $0.61 during midday trading on Friday, reaching $38.83. 296,800 shares of the stock were exchanged, compared to its average volume of 715,573. Crispr Therapeutics has a 1 year low of $22.22 and a 1 year high of $73.90. The company has a debt-to-equity ratio of 0.08, a quick ratio of 15.84 and a current ratio of 15.84. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of -11.29 and a beta of 3.11.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: Stock Selection – What is cash flow?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.